Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) ("Dynavax", "DVAX" or the "Company"), ...

Deep Track Capital, one of the largest shareholders of Dynavax (DVAX) Technologies Corporation, with ownership of approximately 14.53% of the ...

Dynavax's rapid market gains and growth of HEPLISAV-B is complemented by a disciplined and balanced capital allocation framework that weighs investments in internal assets leveraging its novel ...

Heplisav-B (HepB-CpG) is a prescription vaccine used to help prevent infection from the hepatitis B virus. Heplisav-B is given as an injection into your muscle by a healthcare professional.

The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant ...

This study compared the effectiveness of Heplisav-B, a new hepatitis vaccine, vs. standard hepatitis B vaccines as a booster in previously vaccinated individuals. Study approach: Researchers ...

This study compared the effectiveness of Heplisav-B, a new hepatitis vaccine, vs. standard hepatitis B vaccines as a booster in previously vaccinated individuals. Study Approach: Researchers ...

Believes Company’s Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track’s View ...